Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOX, Botensilimab, and Balstilimab in Localized Rectal Cancer
NCT06780787Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- May 2025
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of botensilimab, balstilimab in rectal adenocarcinoma, sponsored by City of Hope. Started May 2025; status: recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06780787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06780787.